Amgen Inc. (TSX:AMGN)
34.26
-0.21 (-0.61%)
Nov 13, 2026, 4:00 PM EST
Amgen Revenue
Amgen had revenue of $10.37B USD in the quarter ending September 30, 2026, with 8.45% growth. This brings the company's total for the last twelve months to $38.90B, up 8.15% year-over-year. In the year 2025, Amgen had annual revenue of $36.75B with 9.95% growth.
Revenue (ttm)
$38.90B
Revenue Growth
+8.15%
P/S Ratio
6.50
Revenue / Employee
$1.24M
Employees
31,500
Market Cap
358.98B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Amgen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.75B | 3.33B | 9.95% |
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | 23.36B | -385.00M | -1.62% |
| Dec 31, 2018 | 23.75B | 898.00M | 3.93% |
| Dec 31, 2017 | 22.85B | -142.00M | -0.62% |
| Dec 31, 2016 | 22.99B | 1.33B | 6.14% |
| Dec 31, 2015 | 21.66B | 1.60B | 7.97% |
| Dec 31, 2014 | 20.06B | 1.39B | 7.43% |
| Dec 31, 2013 | 18.68B | 1.41B | 8.17% |
| Dec 31, 2012 | 17.27B | 1.68B | 10.80% |
| Dec 31, 2011 | 15.58B | 529.00M | 3.51% |
| Dec 31, 2010 | 15.05B | 411.00M | 2.81% |
| Dec 31, 2009 | 14.64B | -361.00M | -2.41% |
| Dec 31, 2008 | 15.00B | 232.00M | 1.57% |
| Dec 31, 2007 | 14.77B | 503.00M | 3.53% |
| Dec 31, 2006 | 14.27B | 1.84B | 14.79% |
| Dec 31, 2005 | 12.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.20B |
| Extendicare | 2.17B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| WELL Health Technologies | 1.56B |
| Sienna Senior Living | 1.08B |
| Vireo Growth | 611.54M |
| Knight Therapeutics | 563.45M |
Amgen News
- 2 hours ago - Amgen price target raised to $430 from $400 at Barclays - TheFly
- 3 days ago - Amgen price target raised to $515 from $460 at Argus - TheFly
- 5 days ago - Amgen's experimental Sjogren's drug meets late-stage trial goal - Reuters
- 5 days ago - Amgen reports results from Phase 3 OASIZ-301 study of dazodalibep - TheFly
- 5 days ago - AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE - PRNewsWire
- 6 days ago - Amgen’s Repatha shows cost-effectiveness in cardiovascular study - TheFly
- 6 days ago - NEW DATA AT AHA 2026 DEMONSTRATES THE VALUE OF TREATMENT WITH REPATHA® EARLIER IN THE CARDIOVASCULAR RISK CONTINUUM - PRNewsWire
- 7 days ago - Novartis drops heart drug after it failed to prevent heart attacks - Stock Analysis